Skip to main content
TipRanks
Go Ultimate75% OFF

CVS Health (CVS) AI Stock Analysis

14,524 Followers
CVS

CVS Health

(NYSE:CVS)

Select Model
Rating:65Neutral
Price Target:$97.00â–²(9.49% Upside)
Action:reiterated
Date:11/05/26

CVS scores solidly overall, led by improving financial momentum and strong cash generation (including raised cash flow guidance) plus an attractive valuation (low P/E and ~3.3% dividend). These positives are tempered by weak technicals (price below major moving averages with negative MACD) and ongoing fundamental constraints from thin margins and a still-meaningful debt load.

Positive Factors
Integrated healthcare platformCVS combines insurance, pharmacy benefit management, retail dispensing and clinical care within one platform. This breadth can support member engagement, utilization steering and cross-selling, while scale in purchasing and contracting may reinforce its competitive position over the next several quarters.
Negative Factors
Thin profitabilityLow current margins leave CVS with limited tolerance for reimbursement pressure, medical-cost inflation or unfavorable business mix. Although earnings have rebounded, profitability remains below earlier periods, making sustained margin improvement important to preserve long-term earnings quality.

CVS Health Key Performance Indicators (KPIs)

Revenue by SegmentBreaks down sales across different business units, revealing which areas contribute most to growth and where the company might face challenges or opportunities.

-$50.00B-$25.00B$0.00$25.00B$50.00B$75.00B$100.00B$125.00BMar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Health Care Benefits and Health Services are clearly the engines of growth and margin recovery—Aetna’s improving MBR and Caremark’s specialty mix and purchasing gains helped management raise guidance and cash‑flow targets—while Pharmacy and Consumer posts steadier, volume‑driven gains but remains exposed to reimbursement and 340B/regulatory pressure. Growing negative intersegment eliminations are increasingly subtracting from consolidated revenue, so prioritize operating income and cash‑flow momentum (where management raised targets) over headline revenue, given 340B uncertainty and expected Caremark membership shifts into 2027.

Data provided by:The Fly

CVS Health (CVS) vs. SPDR S&P 500 ETF (SPY)

-10%0%10%20%30%40%50%CVS+20.08%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$113.35B
Dividend Yield
3.00%
Average Volume (3M)
9.01M
Price to Earnings (P/E)
10.2
Beta (1Y)
0.54
Revenue Growth
6.77%
EPS Growth
2114.64%
Country
US
Employees
259,500
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Plans

CVS Health Business Overview & Revenue Model

Company Description

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Hea...

How the Company Makes Money

CVS Health primarily makes money by generating revenue across three major operating segments—Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness—each with distinct but complementary revenue models. 1) Health Care Benefits (primari...

CVS Health Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:-3.09%|Next Earnings Date:Feb 17, 2027
Earnings Call SentimentPositive

The call was strongly positive. CVS Health reported broad-based third-quarter earnings growth, raised 2026 revenue, adjusted EPS, operating income and cash flow guidance, achieved its leverage goal ahead of schedule and expects to resume share repurchases. Management also presented improving Medicare performance, continued pharmacy growth and a favorable longer-term outlook. The principal challenges were elevated medical cost trends, expected 2027 pressure from 340B and lower Caremark membership, and costs associated with the planned separation, but management characterized these items as manageable and described 2027 as a trough year for Health Services.

Positive Updates

Planned Separation into Two Public Companies
CVS Health announced its intention to separate into two independent publicly traded companies: a healthcare solutions company retaining Aetna, Caremark, Pharmacy Services, Specialty Pharmacy, Oak Street and Signify Health, and CVS Pharmacy, comprising retail pharmacy stores, mail order, MinuteClinic and Health 100. The separation is expected to be tax-free for U.S. federal income tax purposes and completed in the first half of 2028, subject to customary conditions.

Negative Updates

Company Guidance

For full-year 2026, CVS Health raised adjusted earnings per share guidance to at least $8.20 from the prior range of $7.90 to $8.10, expects total revenues of at least $420 billion, Health Care Benefits adjusted operating income of at least $5.4 billion, medical benefit ratio in the lower half of our previously discussed range of 89.75% plus or minus 25-basis-points, Pharmacy and Consumer Wellness adjusted operating income of $6.5 billion, and enterprise adjusted operating income of at least $17.05 billion; cash flow from operations is expected to be at least $15.5 billion, more than $5.5 billion above the initial outlook, while 2027 Health Services adjusted operating income is expected to be at least $7 billion, Pharmacy and Consumer Wellness adjusted operating income is expected to grow low single digits off our current 2026 guidance of $6.5 billion, adjusted EPS is expected to be at least $8.65, reflecting approximately 13% growth off an adjusted 2026 baseline, and the company now believes it will be in the high end of our mid-teens adjusted EPS CAGR through 2028.

CVS Health Financial Statement Overview

Summary

Fundamentals are improving but still constrained by profitability and leverage. TTM revenue growth is very strong (+133%) and earnings rebounded sharply versus 2025, while cash generation is a clear positive (TTM operating cash flow ~$18.7B; free cash flow ~$15.6B, +32%). Offsetting these strengths, margins remain thin (net ~1.2%, operating ~2.1%) and debt remains sizable (~$75.3B) despite improving leverage (debt-to-equity ~1.0).

Income Statement

62Positive

Balance Sheet

58Neutral

Cash Flow

71Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue420.61B402.07B372.81B357.78B322.47B292.11B
Gross Profit59.84B55.36B51.40B54.43B54.50B52.12B
EBITDA19.70B9.86B13.68B18.20B12.35B17.53B
Net Income11.05B1.77B4.61B8.34B4.31B8.00B
Balance Sheet
Total Assets258.07B253.54B253.22B249.73B228.28B233.00B
Cash, Cash Equivalents and Short-Term Investments14.89B10.60B10.99B11.46B15.72B12.53B
Total Debt75.30B79.95B82.92B79.39B70.73B76.00B
Total Liabilities177.39B178.16B177.49B173.09B156.51B157.62B
Stockholders Equity80.50B75.21B75.56B76.46B71.47B75.08B
Cash Flow
Free Cash Flow15.57B7.81B6.33B10.39B13.45B15.74B
Operating Cash Flow18.71B10.64B9.11B13.43B16.18B18.27B
Investing Cash Flow-7.54B-5.87B-7.61B-20.89B-5.05B-5.26B
Financing Cash Flow-8.57B-4.94B-1.14B2.68B-10.52B-11.36B

CVS Health Technical Analysis

Technical Analysis SentimentNeutral
Last Price88.59

Price Trends

50DMA89.09Negative
100DMA94.47Negative
200DMA88.17Positive

Market Momentum

MACD-0.46Negative
RSI49.68Neutral
STOCH84.09Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVS, the sentiment is Neutral. The current price of 88.59 is below the 20-day moving average (MA) of 89.28, below the 50-day MA of 89.09, and above the 200-day MA of 88.17, indicating a neutral trend. The MACD of -0.46 indicates Negative momentum. The RSI at 49.68 is Neutral, neither overbought nor oversold. The STOCH value of 84.09 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CVS.

CVS Health Risk Analysis

CVS Health disclosed 40 risk factors in its most recent earnings report. CVS Health reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

2 New Risks
1.Our Health Care Delivery Businesses Face Unique Risks.Q4, 2024
2.Our recent acquisitions of Signify Health and Oak Street Health subject us to new and additional risks beyond those to which we have been historically subject.Q4, 2023

CVS Health Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CVS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ELVELV76Outperform$96.42B18.9711.59%1.54%3.60%-4.06%
CICI75Outperform$79.09B13.1814.10%2.06%6.79%-0.38%
CNCCNC66Neutral$37.02B25.266.78%―9.71%―
CVSCVS65Neutral$113.35B10.2114.13%3.00%6.77%2114.64%
UNHUNH62Neutral$369.18B23.3916.35%2.20%3.33%-8.75%
HUMHUM58Neutral$55.40B44.416.70%0.77%22.02%-3.07%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%50%100%CVSCNCCIHUMUNHELVDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CVS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CVSCVS Health Corp88.5914.3219.28%
CNCCentene74.7738.82107.98%
CICigna300.1634.2012.86%
HUMHumana461.25235.30104.14%
UNHUnitedhealth Group Inc.412.02110.9536.85%
ELVElevance Health, Inc.446.28136.0843.87%

CVS Health Corporate Events

Business Operations and StrategyM&A Transactions

CVS Health Announces Plan to Separate Into Two Companies

Neutral
Nov 4, 2026

On November 4, 2026, CVS Health announced its intention to separate into two independent, publicly traded companies. One would combine Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health, while CVS Pharmacy would comprise about 9...

Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures

CVS Health refreshes board to drive tech-focused transformation

Positive
Aug 17, 2026

CVS Health announced board changes in August 2026, marking another step in its evolution toward a more technology-focused health solutions model. On August 13, 2026, director Larry M. Robbins resigned after two years on the board, with the company em...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026